ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 646

Comparison of the Lupusqol and SF-36 Scores As Valid Measures of Change in Health Related Quality of Life

Zahi Touma1, Murray B. Urowitz2, Dominique Ibanez2, Shahrzad Taghavi-Zadeh3 and D. D. Gladman3, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Quality of life and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The LupusQoL questionnaire is a disease-specific instrument for adults with lupus while the short form-36 (SF-36) is a generic questionnaire.

We aimed to compare the LupusQoL and the SF-36 questionnaires to determine if they are comparable measures of change in patients with SLE on standard of care therapy.

Methods:

We analyzed the results of SF-36 and LupusQoL questionnaires available from a group of lupus patients who were followed at the Lupus Clinic. Patients were studied if they had at least one follow-up visit within 6 month period while receiving standard of care therapy.

Each of the questionnaires, SF-36 and LupusQoL, includes 8 domains and its scores ranges from 0 (worst possible) to 100 (best possible) quality of life.  The SF-36 subscales can be further summarized into 2 component scores: the physical component summary (PCS) and the mental component summary (MCS).

The mean change in the domains scores for both questionnaires was determined by subtracting the scores of the follow-up visits from the score of the baseline visit.

We determined the correlation (Pearson) of the change in scores of LupusQoL and the change in scores of SF-36. The correlation of the comparable domains of LupusQoL was determined with the corresponding domains of SF-36. For each of the non-comparable domains of the LupusQoL questionnaire the correlation was determined with PCS and MCS individually.

Results:

99 patients (91% F) had baseline and at least one follow-up visit available.  44% were Caucasian, 33% Black, 10% Asian and 12% others. For the 99 patients 251 observations were identified for which both SF-36 and LupusQoL questionnaires were available. Age at lupus diagnosis and lupus duration at first visit were 27.2 ± 12.4 and 11.9 ± 7.7 years.  The mean SLEDAI-2K on all visits was 7.49 ± 5.21.

 

The correlation of the change in scores of the comparable LupusQoL and SF-36 domains ranged from 0.38-0.65.  The correlation between LupusQoL Pain and SF-36 Bodily Pain was 0.65, LupusQoL Physical Health and SF-36 Physical Functioning was 0.38, LupusQoL Emotional Health and SF-36 Mental Health was 0.56 and LupusQoL Fatigue and SF-36 Vitality was 0.48 (all p were significant). For the non-comparable domains the correlation of the LupusQoL domains with SF-36 MCS and PCS ranged from 0.02-0.33 (Table 1).

 

Conclusion:

The correlation of the change in the scores of comparable domains of Lupus QoL and SF-36 ranged from moderate to large. The correlation of the change in the scores of non-comparable domains of Lupus QoL and SF-36 was insubstantial to small. Thus these questionnaires measure different aspects of quality of life and both questionnaires might be used together.

Table 1.  Correlation of change in SF-36 and LupusQoL for comparable and non-comparable domains

 

 

Lupus QoL domains

SF-36 domains

 Comparable domains

Pain

Bodily Pain

0.65 (<0.0001)

Physical Health

Physical Functioning

0.38 (<0.0001)

Emotional Health

Mental Health

0.56 (<0.0001)

Fatigue

Vitality

0.48 (<0.0001)

 Non-comparable domains

Body Image

PCS

MCS

0.09 (0,28)

0.28 (0.0007)

 

Planning

PCS

MCS

0.33 (<0.0001)

0.29 (0.0004)

Intimate Relationships

PCS

MCS

0.27 (0.01)

0.02 (0.89)

Burden to others

PCS

MCS

0.25 (0.002)

0.29 (0.0004)

 


Disclosure:

Z. Touma,
None;

M. B. Urowitz,
None;

D. Ibanez,
None;

S. Taghavi-Zadeh,
None;

D. D. Gladman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-the-lupusqol-and-sf-36-scores-as-valid-measures-of-change-in-health-related-quality-of-life/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology